S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:PASG

Passage Bio Competitors

$19.43
-0.53 (-2.66 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$18.80
Now: $19.43
$21.90
50-Day Range
$17.61
MA: $21.50
$29.83
52-Week Range
$8.09
Now: $19.43
$38.23
Volume408,478 shs
Average Volume511,314 shs
Market Capitalization$892.17 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Passage Bio (NASDAQ:PASG) Vs. SWTX, RVMD, NK, EDIT, NSTG, and SRNE

Should you be buying PASG stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Passage Bio, including SpringWorks Therapeutics (SWTX), Revolution Medicines (RVMD), NantKwest (NK), Editas Medicine (EDIT), NanoString Technologies (NSTG), and Sorrento Therapeutics (SRNE).

Passage Bio (NASDAQ:PASG) and SpringWorks Therapeutics (NASDAQ:SWTX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.

Valuation and Earnings

This table compares Passage Bio and SpringWorks Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Passage BioN/AN/AN/AN/AN/A
SpringWorks TherapeuticsN/AN/A$-58,310,000.00($3.55)-19.52

Analyst Ratings

This is a summary of current recommendations and price targets for Passage Bio and SpringWorks Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Passage Bio02602.75
SpringWorks Therapeutics00303.00

Passage Bio currently has a consensus target price of $25.5297, indicating a potential upside of 31.39%. SpringWorks Therapeutics has a consensus target price of $91.00, indicating a potential upside of 31.31%. Given Passage Bio's higher probable upside, research analysts clearly believe Passage Bio is more favorable than SpringWorks Therapeutics.

Insider and Institutional Ownership

67.6% of Passage Bio shares are owned by institutional investors. Comparatively, 76.3% of SpringWorks Therapeutics shares are owned by institutional investors. 51.2% of SpringWorks Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Passage Bio and SpringWorks Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Passage BioN/AN/AN/A
SpringWorks TherapeuticsN/A-24.48%-23.58%

Summary

Passage Bio beats SpringWorks Therapeutics on 4 of the 7 factors compared between the two stocks.

Revolution Medicines (NASDAQ:RVMD) and Passage Bio (NASDAQ:PASG) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, valuation, profitability and institutional ownership.

Profitability

This table compares Revolution Medicines and Passage Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Revolution Medicines-191.17%-32.25%-20.55%
Passage BioN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Revolution Medicines and Passage Bio, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Revolution Medicines01402.80
Passage Bio02602.75

Revolution Medicines currently has a consensus price target of $50.75, suggesting a potential upside of 19.55%. Passage Bio has a consensus price target of $25.5297, suggesting a potential upside of 31.39%. Given Passage Bio's higher probable upside, analysts clearly believe Passage Bio is more favorable than Revolution Medicines.

Institutional & Insider Ownership

85.8% of Revolution Medicines shares are held by institutional investors. Comparatively, 67.6% of Passage Bio shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Revolution Medicines and Passage Bio's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revolution Medicines$50.04 million56.31$-47,660,000.00N/AN/A
Passage BioN/AN/AN/AN/AN/A

Passage Bio has lower revenue, but higher earnings than Revolution Medicines.

Summary

Passage Bio beats Revolution Medicines on 5 of the 8 factors compared between the two stocks.

Passage Bio (NASDAQ:PASG) and NantKwest (NASDAQ:NK) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, earnings and profitability.

Valuation and Earnings

This table compares Passage Bio and NantKwest's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Passage BioN/AN/AN/AN/AN/A
NantKwest$40,000.0070,166.82$-65,790,000.00($0.70)-36.79

Passage Bio has higher earnings, but lower revenue than NantKwest.

Profitability

This table compares Passage Bio and NantKwest's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Passage BioN/AN/AN/A
NantKwest-76,658.58%-56.06%-46.93%

Analyst Ratings

This is a breakdown of recent ratings for Passage Bio and NantKwest, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Passage Bio02602.75
NantKwest00103.00

Passage Bio currently has a consensus price target of $25.5297, suggesting a potential upside of 31.39%. NantKwest has a consensus price target of $18.00, suggesting a potential downside of 30.10%. Given Passage Bio's higher possible upside, analysts clearly believe Passage Bio is more favorable than NantKwest.

Insider and Institutional Ownership

67.6% of Passage Bio shares are owned by institutional investors. Comparatively, 9.4% of NantKwest shares are owned by institutional investors. 71.7% of NantKwest shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Passage Bio beats NantKwest on 6 of the 9 factors compared between the two stocks.

Editas Medicine (NASDAQ:EDIT) and Passage Bio (NASDAQ:PASG) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Profitability

This table compares Editas Medicine and Passage Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Editas Medicine-99.62%-26.74%-16.38%
Passage BioN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations for Editas Medicine and Passage Bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Editas Medicine34302.00
Passage Bio02602.75

Editas Medicine currently has a consensus target price of $49.2222, suggesting a potential upside of 21.96%. Passage Bio has a consensus target price of $25.5297, suggesting a potential upside of 31.39%. Given Passage Bio's stronger consensus rating and higher possible upside, analysts plainly believe Passage Bio is more favorable than Editas Medicine.

Institutional & Insider Ownership

87.5% of Editas Medicine shares are owned by institutional investors. Comparatively, 67.6% of Passage Bio shares are owned by institutional investors. 0.9% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Editas Medicine and Passage Bio's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Editas Medicine$20.53 million132.43$-133,750,000.00($2.68)-15.06
Passage BioN/AN/AN/AN/AN/A

Passage Bio has lower revenue, but higher earnings than Editas Medicine.

Summary

Passage Bio beats Editas Medicine on 6 of the 9 factors compared between the two stocks.

NanoString Technologies (NASDAQ:NSTG) and Passage Bio (NASDAQ:PASG) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation and earnings.

Institutional and Insider Ownership

98.3% of NanoString Technologies shares are held by institutional investors. Comparatively, 67.6% of Passage Bio shares are held by institutional investors. 4.2% of NanoString Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and recommmendations for NanoString Technologies and Passage Bio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NanoString Technologies01502.83
Passage Bio02602.75

NanoString Technologies currently has a consensus target price of $63.00, indicating a potential upside of 3.26%. Passage Bio has a consensus target price of $25.5297, indicating a potential upside of 31.39%. Given Passage Bio's higher probable upside, analysts plainly believe Passage Bio is more favorable than NanoString Technologies.

Valuation & Earnings

This table compares NanoString Technologies and Passage Bio's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NanoString Technologies$125.57 million21.41$-40,700,000.00($1.93)-31.61
Passage BioN/AN/AN/AN/AN/A

Passage Bio has lower revenue, but higher earnings than NanoString Technologies.

Profitability

This table compares NanoString Technologies and Passage Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NanoString Technologies-53.47%-68.96%-24.15%
Passage BioN/AN/AN/A

Summary

Passage Bio beats NanoString Technologies on 5 of the 9 factors compared between the two stocks.

Sorrento Therapeutics (NASDAQ:SRNE) and Passage Bio (NASDAQ:PASG) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Insider and Institutional Ownership

27.4% of Sorrento Therapeutics shares are owned by institutional investors. Comparatively, 67.6% of Passage Bio shares are owned by institutional investors. 3.4% of Sorrento Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Sorrento Therapeutics and Passage Bio's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sorrento Therapeutics$31.43 million78.73$-292,070,000.00($2.12)-4.16
Passage BioN/AN/AN/AN/AN/A

Passage Bio has lower revenue, but higher earnings than Sorrento Therapeutics.

Profitability

This table compares Sorrento Therapeutics and Passage Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sorrento Therapeutics-698.01%-314.06%-43.60%
Passage BioN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Sorrento Therapeutics and Passage Bio, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sorrento Therapeutics00403.00
Passage Bio02602.75

Sorrento Therapeutics currently has a consensus price target of $28.75, indicating a potential upside of 226.33%. Passage Bio has a consensus price target of $25.5297, indicating a potential upside of 31.39%. Given Sorrento Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Sorrento Therapeutics is more favorable than Passage Bio.

Summary

Passage Bio beats Sorrento Therapeutics on 5 of the 9 factors compared between the two stocks.


Passage Bio Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$69.30-7.8%$3.39 billionN/A-39.83Analyst Report
Revolution Medicines logo
RVMD
Revolution Medicines
1.6$42.45-1.7%$2.82 billion$50.04 million0.00Earnings Announcement
Analyst Report
NantKwest logo
NK
NantKwest
1.1$25.75-3.2%$2.81 billion$40,000.00-36.27Decrease in Short Interest
Gap Up
Editas Medicine logo
EDIT
Editas Medicine
1.4$40.36-6.9%$2.72 billion$20.53 million-23.20Analyst Report
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$61.01-12.9%$2.69 billion$125.57 million-35.68Earnings Announcement
Analyst Report
Gap Up
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$8.81-3.0%$2.47 billion$31.43 million-6.03Gap Up
AlloVir logo
ALVR
AlloVir
1.4$34.53-7.5%$2.25 billionN/A0.00Insider Selling
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.8$45.86-1.9%$2.04 billionN/A0.00
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$10.92-8.7%$1.94 billion$48.83 million-14.37
bluebird bio logo
BLUE
bluebird bio
1.8$27.94-5.0%$1.88 billion$44.67 million-2.54Analyst Report
Vericel logo
VCEL
Vericel
1.5$40.41-4.2%$1.86 billion$117.85 million-4,041,000.00Analyst Report
Analyst Revision
Scholar Rock logo
SRRK
Scholar Rock
1.3$50.60-1.7%$1.70 billion$20.49 million-21.00Upcoming Earnings
News Coverage
Gap Up
Ocugen logo
OCGN
Ocugen
1.1$8.97-16.6%$1.69 billionN/A-6.06Analyst Report
Unusual Options Activity
Gap Up
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.1$39.07-2.5%$1.68 billionN/A0.00
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.23-0.3%$1.61 billion$102.43 million-18.72Analyst Downgrade
Analyst Revision
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$71.65-16.2%$1.59 billionN/A-48.41Earnings Announcement
Analyst Upgrade
Analyst Revision
Translate Bio logo
TBIO
Translate Bio
1.4$21.29-0.8%$1.58 billion$7.80 million-19.90Upcoming Earnings
Analyst Revision
News Coverage
Replimune Group logo
REPL
Replimune Group
1.5$32.30-1.3%$1.50 billionN/A-18.25News Coverage
REGENXBIO logo
RGNX
REGENXBIO
1.8$39.21-2.4%$1.47 billion$35.23 million-15.81Earnings Announcement
Analyst Downgrade
Analyst Revision
FMTX
Forma Therapeutics
1.8$33.42-8.4%$1.38 billion$100.56 million0.00Decrease in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.6$15.89-0.4%$1.33 billionN/A-3.44Earnings Announcement
Analyst Upgrade
Analyst Revision
Alector logo
ALEC
Alector
1.3$16.25-1.0%$1.29 billion$21.22 million-7.29Analyst Upgrade
Immunovant logo
IMVT
Immunovant
1.8$13.08-7.0%$1.28 billionN/A-10.14Increase in Short Interest
PCVX
Vaxcyte
1.8$23.62-9.4%$1.20 billionN/A0.00Insider Selling
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$15.25-1.2%$1.11 billion$356.07 million7.47Analyst Report
Mesoblast logo
MESO
Mesoblast
1.4$9.18-0.3%$1.08 billion$32.16 million-10.43Earnings Announcement
Analyst Upgrade
Analyst Revision
Cortexyme logo
CRTX
Cortexyme
1.3$36.37-3.2%$1.07 billionN/A-15.15Earnings Announcement
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$10.96-3.1%$1.07 billion$250,000.00-8.63Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Inhibrx logo
INBX
Inhibrx
1.7$26.56-9.9%$1.00 billionN/A0.00
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$19.25-1.6%$903.15 million$69.89 million-4.59
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$23.40-7.7%$883.61 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Down
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$23.73-8.0%$857.03 millionN/A-3.92News Coverage
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.7$10.40-10.4%$844.29 millionN/A-4.86
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.54-12.1%$821.06 millionN/A0.00
Cellectis logo
CLLS
Cellectis
1.2$19.31-4.3%$820.41 million$22.99 million-10.27
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.06-6.9%$804.13 millionN/A-9.94
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.29-4.7%$783.28 million$42.74 million-225.44
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.01-4.8%$775.44 million$1.12 million-5.06Analyst Upgrade
Vaxart logo
VXRT
Vaxart
1.3$5.92-7.4%$697.18 million$9.86 million-10.03Analyst Report
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.86-7.3%$667.23 million$2.51 million-4.16Earnings Announcement
Analyst Report
Increase in Short Interest
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.29-6.8%$626.64 millionN/A0.00Decrease in Short Interest
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$30.61-8.2%$622.00 millionN/A0.00Increase in Short Interest
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.16-7.3%$600.87 million$150.05 million-2.90
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$11.02-3.1%$578.33 million$22.24 million-5.48Upcoming Earnings
Analyst Report
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$9.28-17.0%$573.69 millionN/A-1.35
Compugen logo
CGEN
Compugen
1.4$8.16-9.2%$558.31 million$17.80 million-22.05Analyst Downgrade
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.02-7.6%$551.49 million$14.75 million-2.15Gap Up
Curis logo
CRIS
Curis
1.3$9.13-6.4%$537.00 million$10 million-11.13Increase in Short Interest
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.90-2.5%$533.93 million$13.29 million-9.86Upcoming Earnings
News Coverage
Solid Biosciences logo
SLDB
Solid Biosciences
1.1$8.83-12.0%$533.77 millionN/A-4.29Upcoming Earnings
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.